If you're wondering what diagnosis code to report in support of preoperative Covid-19 screening tests, the FY 2024 ICD-10-CM Official Guidelines for Coding and Reporting has the answer: Assign code Z11.52 (Encounter for screening for COVID-19), the newly updated guidelines instruct.
The FY2024 ICD-10-CM guidelines, issued July 5, will take effect Oct. 1 along with the finalized code changes, which were released June 16
(For more, see the Part B News blog post of the same date).
In addition to the new clarification on preoperative Covid-19 screening (I.C.1.g.1.f), the FY2024 guidelines include a range of other changes scattered throughout, including:
Under I.C.9.e. Acute Myocardial Infarction (AMI), a new paragraph for Myocardial Infarction with Coronary Microvascular Dysfunction has been added to state:
- "Coronary microvascular dysfunction (CMD) is a condition that impacts the microvasculature by restricting microvascular flow and increasing microvascular resistance. Code I21.B, Myocardial infarction with coronary microvascular dysfunction, is assigned for myocardial infarction with coronary microvascular disease, myocardial infarction with coronary microvascular dysfunction, and myocardial infarction with non-obstructive coronary arteries (MINOCA) with microvascular disease." (I.C.9.e.6))
When coding a coma, you are to assign code R40.20 (Unspecified coma) "when the underlying cause of the coma is not known, or the cause is a traumatic brain injury and the coma scale is not documented in the medical record," states a new guideline added to Chapter 18 (I.C.18.e.)
An additional new note instructs that coma scale codes (R40.21- to R40.24-) "cannot be used with R402A (Nontraumatic coma due to underlying condition)." (I.C.18.e.1))
When coding follow-up care after treatment of neoplasms, note the new guideline added for codes Z08 and Z09:
"Codes Z08, Encounter for follow-up examination after completed treatment for malignant neoplasm, and Z09, Encounter for follow up examination after completed treatment for conditions other than malignant neoplasm, may be assigned following any type of completed treatment modality (including both medical and surgical treatments)." (I.C.21.c.8))
For more detailed coverage, see future issues of DecisionHealth newsletters.